Characterization of the topoisomerase II-induced cleavage sites in the c-myc proto-oncogene. In vitro stimulation by the antitumoral intercalating drug mAMSA.
In an attempt to get an insight into the activity of mAMSA (a DNA topoisomerase II-mediated drug) on the human proto-oncogene c-myc, an in vitro system consisting of purified calf thymus DNA topoisomerase II and a c-myc DNA inserted in lambda phage was utilized. The occurrence of discrete bands, detected by hybridization of Southern blots with appropriate c-myc probes, indicated the presence of cleavage sites in the sole presence of DNA topoisomerase II. The band intensity increased in the presence of mAMSA, while no significant difference occurred in the cleavage pattern. The location of the cleavage sites along the c-myc locus revealed a striking correspondence with that of some DNase hypersensitive sites. These results indicate that DNA topoisomerase II is most certainly implicated in the mAMSA activity and that the drug stimulates the topoisomerase II cleaving activity at specific sites, which may be involved in the biological activity of the drug.
D000677:Amsacrine / Q000494:pharmacology*; D000818:Animals; D010582:Bacteriophage lambda / Q000235:genetics; D002417:Cattle; D004247:DNA / Q000378:metabolism*; D004262:DNA Restriction Enzymes; D004250:DNA Topoisomerases, Type II / Q000378:metabolism*; D004274:DNA, Recombinant / Q000378:metabolism; D004996:Ethidium / Q000494:pharmacology; D006801:Humans; D009693:Nucleic Acid Hybridization; D009857:Oncogenes; D000090063:Proto-Oncogene Mas
D004274:DNA, Recombinant; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D000677:Amsacrine; D004247:DNA; D004262:DNA Restriction Enzymes; D004250:DNA Topoisomerases, Type II; D004996:Ethidium